Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 May 4:9:875327.
doi: 10.3389/fcvm.2022.875327. eCollection 2022.

Effect of Sodium-Glucose Cotransporter 2 Inhibitors for Heart Failure With Preserved Ejection Fraction: A Systematic Review and Meta-Analysis of Randomized Clinical Trials

Hufang Zhou  1 , Wenhua Peng  1 , Fuyao Li  1 , Yuelin Wang  2 , Baofu Wang  1 , Yukun Ding  1 , Qian Lin  3 , Ying Zhao  4 , Guozhong Pan  1 , Xian Wang  1
Affiliations

Effect of Sodium-Glucose Cotransporter 2 Inhibitors for Heart Failure With Preserved Ejection Fraction: A Systematic Review and Meta-Analysis of Randomized Clinical Trials

Hufang Zhou et al. Front Cardiovasc Med. .

Abstract

Background: Heart failure with preserved ejection fraction (HFpEF) is associated with a high risk of mortality and frequent hospitalization. Sodium-glucose cotransporter 2 (SGLT2) inhibitors have favorable cardiovascular protective effect and could decrease the risk of mortality and hospitalization in patients with heart failure with reduced ejection fraction. However, the effect of SGLT2 inhibitors for HFpEF has not been well studied.

Purpose: The aim of this meta-analysis is to systematically assess the effects of SGLT2 inhibitors in patients with HFpEF.

Methods: MEDLINE, EMBASE, Ovid, Cochrane Library, Chinese National Knowledge Infrastructure Database, VIP database, Chinese Biomedical Database, and Wanfang Database were searched from inception to November 2021 for randomized controlled trials (RCTs) of SGLT2 inhibitors for HFpEF. Risk bias was assessed for included studies according to Cochrane handbook. The primary outcome was the composite of first hospitalization for heart failure (HHF) or cardiovascular mortality. First HHF, cardiovascular mortality, total HHF, all-cause mortality, exercise capacity, ventricular diastolic function, and adverse events were considered as secondary endpoints. PROSPERO registration: CRD42021291122.

Results: A total of 12 RCTs including 10,883 patients with HFpEF (SGLT2 inhibitors group: 5,621; control group: 5,262) were included. All included RCTs were at low risk of bias. Meta-analysis showed that SGLT2 inhibitors significantly reduced the composite of first HHF or cardiovascular mortality (HR:0.78, 95% CI: [0.70, 0.87], P< 0.00001, I 2 = 0%), first HHF (HR:0.71, 95% CI: [0.62, 0.83], P < 0.00001, I 2 = 0%), total HHF (RR:0.75, 95% CI: [0.67, 0.84], P<0.00001, I 2 = 0%), E/e' (MD: -1.22, 95% CI: [-2.29, -0.15], P = 0.03, I 2 = 59%) and adverse events (RR:0.92, 95% CI: [0.88, 0.97], P = 0.001, I 2 = 0%). No statistical differences were found in terms of cardiovascular mortality, all-cause mortality, NT-proBNP, BNP and 6-min walk test distance.

Conclusion: SGLT2 inhibitors significantly improve cardiovascular outcomes with a lower risk of serious adverse events in patients with HFpEF. However, these findings require careful recommendation due to the small number of RCTs at present. More multi-center, randomized, double-blind, placebo-controlled trials are needed.

Systematic review registration: [https://www.crd.york.ac.Uk/prospero/], identifier [CRD42021291122].

Keywords: heart failure with preserved ejection fraction; meta-analysis; randomized controlled trials; sodium-glucose cotransporter 2 inhibitors; systematic review.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

FIGURE 1
FIGURE 1
The flow chart of the study selection process showing how to screen eligible randomized controlled trials.
FIGURE 2
FIGURE 2
Risk of bias summary.
FIGURE 3
FIGURE 3
Forest plot displaying the effects of SGLT2 inhibitors vs. placebo for composite of cardiovascular death or first hospitalization arises from heart failure in HFpEF patients.
FIGURE 4
FIGURE 4
Forest plot displaying the results of subgroup analysis by various thresholds of ejection fraction used in the diagnosis of HFpEF.
FIGURE 5
FIGURE 5
Forest plot displaying the results of subgroup analysis by types of studies.
FIGURE 6
FIGURE 6
Forest plot displaying the effects of SGLT2 inhibitors vs. placebo for first hospitalization for heart failure in HFpEF patients.
FIGURE 7
FIGURE 7
Forest plot displaying the effects of SGLT2 inhibitors vs. placebo for cardiovascular death in HFpEF patients.
FIGURE 8
FIGURE 8
Forest plot displaying the effects of SGLT2 inhibitors vs. placebo for total hospitalization for heart failure in HFpEF patients.
FIGURE 9
FIGURE 9
Forest plot displaying the effects of SGLT2 inhibitors vs. placebo for all-cause mortality in HFpEF patients.
FIGURE 10
FIGURE 10
Forest plot displaying the effects of SGLT2 inhibitors vs. placebo for E/e’ in HFpEF patients.
FIGURE 11
FIGURE 11
Forest plot displaying the effects of SGLT2 inhibitors vs. placebo for adverse events in HFpEF patients.
FIGURE 12
FIGURE 12
Funnel plot of the included trials with composite of cardiovascular death or first hospitalization for heart failure data.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. (2021) 42:3599–726. - PubMed
    1. Conrad N, Judge A, Tran J, Mohseni H, Hedgecott D, Crespillo AP, et al. Temporal trends and patterns in heart failure incidence: a population-based study of 4 million individuals. Lancet. (2018) 391:572–80. 10.1016/S0140-6736(17)32520-5 - DOI - PMC - PubMed
    1. Steinberg BA, Zhao X, Heidenreich PA, Peterson ED, Bhatt DL, Cannon CP, et al. Trends in patients hospitalized with heart failure and preserved left ventricular ejection fraction: prevalence, therapies, and outcomes. Circulation. (2012) 126:65–75. 10.1161/CIRCULATIONAHA.111.080770 - DOI - PubMed
    1. Dunlay SM, Roger VL, Redfield MM. Epidemiology of heart failure with preserved ejection fraction. Nat Rev Cardiol. (2017) 14:591–602. 10.1038/nrcardio.2017.65 - DOI - PubMed
    1. Pfeffer MA, Shah AM, Borlaug BA. Heart failure with preserved ejection fraction in perspective. Circ Res. (2019) 124:1598–617. - PMC - PubMed

Publication types